The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

Andreja Figurek; Merita Rroji; Goce Spasovski

doi:10.3390/cells10051266

The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

Cells. 2021 May 20;10(5):1266. doi: 10.3390/cells10051266.

Authors

Andreja Figurek^{1

2}, Merita Rroji³, Goce Spasovski⁴

Affiliations

¹ Department of Internal Medicine, Medical Faculty, University of Banja Luka, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
² Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland.
³ Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, 1001 Tirana, Albania.
⁴ Department of Nephrology, Medical Faculty, University of Ss. Cyril and Methodius, 1000 Skopje, North Macedonia.

Abstract

Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.

Keywords: FGF signaling; FGF23; Wnt pathway; cardiomyocyte; klotho.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Biomarkers / metabolism*
Fibroblast Growth Factor-23
Fibroblast Growth Factors / metabolism*
Humans
Myocytes, Cardiac / metabolism*
Renal Insufficiency, Chronic / metabolism
Renal Insufficiency, Chronic / physiopathology*

Substances

Biomarkers
FGF23 protein, human
Fibroblast Growth Factors
Fibroblast Growth Factor-23